A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad207 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Courtney Woolsey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Hemorrhagic Fever, Ebola, Ebolavirus, Vesicular Stomatitis, Viral Vaccines. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, HHS.
Abstract (Originalsprache)
Background
The filovirus Bundibugyo virus (BDBV) causes severe disease with a mortality rate of approximately 20%–51%. The only licensed filovirus vaccine in the United States, Ervebo, consists of a recombinant vesicular stomatitis virus (rVSV) vector that expresses Ebola virus (EBOV) glycoprotein (GP). Ervebo was shown to rapidly protect against fatal Ebola disease in clinical trials; however, the vaccine is only indicated against EBOV. Recent outbreaks of other filoviruses underscore the need for additional vaccine candidates, particularly for BDBV infections.
Methods
To examine whether the rVSV vaccine candidate rVSVΔG/BDBV-GP could provide therapeutic protection against BDBV, we inoculated seven cynomolgus macaques with 1000 plaque-forming units of BDBV, administering rVSVΔG/BDBV-GP vaccine to 6 of them 20–23 minutes after infection.
Results
Five of the treated animals survived infection (83%) compared to an expected natural survival rate of 21% in this macaque model. All treated animals showed an early circulating immune response, while the untreated animal did not. Surviving animals showed evidence of both GP-specific IgM and IgG production, while animals that succumbed did not produce significant IgG.
Conclusions
This small, proof-of-concept study demonstrated early treatment with rVSVΔG/BDBV-GP provides a survival benefit in this nonhuman primate model of BDBV infection, perhaps through earlier initiation of adaptive immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA.
- National Emerging Infectious Diseases Laboratories, Boston University, Boston, Massachusetts, USA.
- Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
ORCID-Profile: John H Connor, Thomas W Geisbert
Förderung
- NIAID NIH HHS
- NIH HHS
- HHS
- Department of Health and Human Services
- National Institutes of Health
- University of Texas Medical Branch
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Woolsey, C., Strampe, J., Fenton, K. A., Agans, K. N., Martinez, J., Borisevich, V., Dobias, N. S., Deer, D. J., Geisbert, J. B., Cross, R. W., Connor, J. H., & Geisbert, T. W. (2023). A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad207
Vancouver
Woolsey C, Strampe J, Fenton KA, Agans KN, Martinez J, Borisevich V, et al. A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad207
BibTeX
@article{Woolsey2023,
author = {Woolsey, Courtney and Strampe, Jamie and Fenton, Karla A and Agans, Krystle N and Martinez, Jasmine and Borisevich, Viktoriya and Dobias, Natalie S and Deer, Daniel J and Geisbert, Joan B and Cross, Robert W and Connor, John H and Geisbert, Thomas W},
title = {A Recombinant Vesicular Stomatitis Virus–Based Vaccine Provides Postexposure Protection Against Bundibugyo Ebolavirus Infection},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad207}
}
EUVIMED